Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis.
Description | Linzagolix is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which is under development by Kissei Pharmaceutical and ObsEva for the treatment of uterine fibroids, endometriosis, and adenomyosis. As of December 2020, it is under review for approval for uterine fibroids, is in phase III clinical trials for endometriosis, and is in phase II clinical studies for adenomyosis. |
Molecular Weight | 508.42 |
Formula | C22H15F3N2O7S |
CAS No. | 935283-04-8 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 55 mg/ml (108.18 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Linzagolix 935283-04-8 GPCR/G Protein GNRH Receptor KLH 2109 endometriosis KLH-2109 GnRH Receptor Gonadotropin releasing hormone receptor inhibit uterine fibroids KLH2109 GNRHR adenomyosis OBE 2109 Inhibitor OBE-2109 OBE2109 inhibitor